Metastatic Pancreatic Cancer: ASCO Guideline Update | Zendy

Davendra Sohal | Zendy; Erin B. Kennedy | Zendy; Pelin Cinar | Zendy; Thierry Conroy | Zendy; Mehmet Sitki Copur | Zendy; Christopher H. Crane | Zendy; Ignacio GarridoLaguna | Zendy; M. Lau | Zendy; Tyler Johnson | Zendy; Smitha Krishnamurthi | Zendy; Cassadie Moravek | Zendy; Eileen M. O’Reilly | Zendy; Philip A. Philip | Zendy; Shubham Pant | Zendy; Manish A. Shah | Zendy; Vaibhav Sahai | Zendy; Hope E. Uronis | Zendy; Neeha Zaidi | Zendy; Daniel A. Laheru | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metastatic Pancreatic Cancer: ASCO Guideline Update

Author(s) -

Davendra Sohal,

Erin B. Kennedy,

Pelin Cinar,

Thierry Conroy,

Mehmet Sitki Copur,

Christopher H. Crane,

Ignacio GarridoLaguna,

M. Lau,

Tyler Johnson,

Smitha Krishnamurthi,

Cassadie Moravek,

Eileen M. O’Reilly,

Philip A. Philip,

Shubham Pant,

Manish A. Shah,

Vaibhav Sahai,

Hope E. Uronis,

Neeha Zaidi,

Daniel A. Laheru

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.01364

Subject(s) - medicine , guideline , olaparib , microsatellite instability , oncology , clinical trial , pancreatic cancer , cancer , pembrolizumab , intensive care medicine , pathology , immunotherapy , biochemistry , chemistry , allele , polymerase , poly adp ribose polymerase , microsatellite , gene

PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment.METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer.RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update.RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research